Analysts expect that Pharming Group (NASDAQ:PHGUF) will announce earnings of ($0.01) per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Pharming Group’s earnings. The lowest EPS estimate is ($0.01) and the highest is $0.00. Pharming Group also reported earnings per share of ($0.01) during the same quarter last year. The company is expected to issue its next earnings results on Thursday, October 26th.

According to Zacks, analysts expect that Pharming Group will report full year earnings of ($0.08) per share for the current fiscal year, with EPS estimates ranging from ($0.09) to ($0.06). For the next fiscal year, analysts forecast that the company will report earnings of $0.01 per share, with EPS estimates ranging from ($0.01) to $0.03. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that cover Pharming Group.

Shares of Pharming Group (PHGUF) remained flat at $0.48 during trading on Monday. The firm’s market cap is $242.70 million. Pharming Group has a 52 week low of $0.17 and a 52 week high of $0.55.

COPYRIGHT VIOLATION NOTICE: This piece was posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at

Pharming Group Company Profile

Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies.

Get a free copy of the Zacks research report on Pharming Group (PHGUF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with's FREE daily email newsletter.